Moffitt Notice of Blackbaud Data Incident. Learn More
Clinical Trials Search
Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study
This study will treat resectable cutaneous squamous cell carcinoma patients with pramlintide for two weeks prior to surgical resection of their tumor. Pre-treatment and surgical resection specimens will then be analyzed for biological alterations.
The purpose of the study is to: 1) Determine the feasibility of patients willing to self-inject pramlintide up to three times daily for two weeks prior to surgical resection of their tumor. 2) Determine if two weeks of SQ pramlintide injections prior to surgery are safe 3) Determine if tissues collected pre- and post- treatment demonstrate detectable biological changes in response to pramlintide treatment